Key information

🔎 Fund Overview

Ascentage Pharma Group International is a holding company primarily engaged in discovering, developing and commercializing therapies primarily in hematological malignancies. The Company’s main business is engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus and certain age-related diseases. The Company’s main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918 and other products. The Company’s products are mainly used to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. The Company mainly conducts its business in the domestic market.